Please enable Javascript
Conferences
Partners
Expert Interviews
Subscribe
Breast Cancers Today
HER2 Breast Cancer
HR Breast Cancer
Triple-Negative Breast Cancer
Genetics & Breast Cancer
Gastro Today
Inflammatory Bowel Disease
Irritable Bowel Syndrome
Hepatitis
Heme Today
Anemia
Deep Vein Thrombosis
Essential Thrombocythemia
Hemophilia
Immune Thrombocytopenic Purpura
Myelodysplastic Syndromes
Myelofibrosis
Myeloproliferative Neoplasms
PNH
Polycythemia Vera
Pulmonary Embolism
Sickle Cell Disease
Thrombocytopenia
Thrombophilia
Thrombosis
Thrombotic Thrombocytopenic Purpura
Venous Thromboembolism
von Willebrand Disease
Metabolic Care Today
Diabetes
Obesity
Nephrology Times
Acute Kidney Injury
ADPKD
Anemia and Kidney Disease
Chronic Kidney Disease
COVID-19 and Kidney Disease
Diabetes and Hypertension
End-Stage Renal Disease
Gout
Hyperkalemia
IgAN
Kidney Transplantation
Metabolic Acidosis
Sleep
More
Career News
Future of Medicine
Health and Wellness
— HIV
Infectious Diseases
Lupus
Neurology
Oncology
Ophthalmology
— Demodex Blepharitis
Orthopedics
Pharmacology
Pulmonology
Rheumatology
Urology
Erica Barnell, MD, PhD
Erica Barnell, MD, PhD, of Washington University School of Medicine, and founder of Geneoscopy Inc
Articles by Erica Barnell, MD, PhD
FDA Approves Noninvasive Multitarget Stool RNA Test for Colorectal Cancer
Erica Barnell, MD, PhD
Colorectal Cancer
|
July 10, 2025
Dr. Barnell gives an update on the FDA approval of ColoSense and how the test can aid in public health initiatives.
View More
Noninvasive Multitarget Stool RNA Test Proves Sensitive for Colorectal Cancer, Advanced Adenomas
Erica Barnell, MD, PhD
Colorectal Cancer
|
July 10, 2025
Dr. Barnell describes the "ColoSense" test and the study that showed its superior sensitivity and specificity vs colonoscopy.
View More